Cogent Biosciences (COGT) Retained Earnings (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Retained Earnings data on file, last reported at -$1.3 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 38.04% year-over-year to -$1.3 billion in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 38.04% decrease from a year earlier, with the FY2025 full-year figure at $355000.0, down 20.58% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.3 billion, down from $355000.0 in the prior quarter.
• Over the last five years, Retained Earnings for COGT reached as high as $447000.0 in Q4 2024 and fell as low as -$1.3 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$432.9 million across 5 years, with a median of -$336.5 million in 2022.
• Across the five-year window, Retained Earnings jumped 100.06% in 2023 and plunged 4137425.0% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$411.2 million in 2022, then soared by 100.06% to $246000.0 in 2023, then surged by 81.71% to $447000.0 in 2024, then fell by 20.58% to $355000.0 in 2025, then sank by 362297.18% to -$1.3 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.3 billion in Q1 2026, $355000.0 in Q4 2025, and -$1.1 billion in Q3 2025.